Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.

Hartwell KJ, Lematty T, McRae-Clark AL, Gray KM, George MS, Brady KT.

Am J Drug Alcohol Abuse. 2013 Mar;39(2):92-8. doi: 10.3109/00952990.2012.750665.

2.

Effects of varenicline on smoking cue–triggered neural and craving responses.

Franklin T, Wang Z, Suh JJ, Hazan R, Cruz J, Li Y, Goldman M, Detre JA, O'Brien CP, Childress AR.

Arch Gen Psychiatry. 2011 May;68(5):516-26. doi: 10.1001/archgenpsychiatry.2010.190. Epub 2011 Jan 3.

3.

The effects of varenicline on stress-induced and cue-induced craving for cigarettes.

Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K.

Drug Alcohol Depend. 2013 Jul 1;131(1-2):136-42. doi: 10.1016/j.drugalcdep.2012.12.015. Epub 2013 Jan 5.

PMID:
23298651
4.

Neural correlates of craving and resisting craving for tobacco in nicotine dependent smokers.

Hartwell KJ, Johnson KA, Li X, Myrick H, LeMatty T, George MS, Brady KT.

Addict Biol. 2011 Oct;16(4):654-66. doi: 10.1111/j.1369-1600.2011.00340.x. Epub 2011 Jul 25.

5.

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.

West R, Baker CL, Cappelleri JC, Bushmakin AG.

Psychopharmacology (Berl). 2008 Apr;197(3):371-7. Epub 2007 Dec 15.

PMID:
18084743
6.

Impact of varenicline on cue-specific craving assessed in the natural environment among treatment-seeking smokers.

Gass JC, Wray JM, Hawk LW, Mahoney MC, Tiffany ST.

Psychopharmacology (Berl). 2012 Sep;223(1):107-16. doi: 10.1007/s00213-012-2698-9. Epub 2012 Apr 4.

7.

A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.

Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, Davies S, Caro JJ.

Pharmacoeconomics. 2011 Jun;29(6):497-510. doi: 10.2165/11589230-000000000-00000.

PMID:
21452908
8.

Effects of varenicline and cognitive bias modification on neural response to smoking-related cues: study protocol for a randomized controlled study.

Attwood AS, Williams T, Adams S, McClernon FJ, Munafò MR.

Trials. 2014 Oct 7;15:391. doi: 10.1186/1745-6215-15-391.

9.

Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study.

Goudriaan AE, de Ruiter MB, van den Brink W, Oosterlaan J, Veltman DJ.

Addict Biol. 2010 Oct;15(4):491-503. doi: 10.1111/j.1369-1600.2010.00242.x. Epub 2010 Sep 14.

10.

The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults.

Cortese BM, Uhde TW, Brady KT, McClernon FJ, Yang QX, Collins HR, LeMatty T, Hartwell KJ.

Psychiatry Res. 2015 Dec 30;234(3):321-7. doi: 10.1016/j.pscychresns.2015.10.008. Epub 2015 Oct 9.

11.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
12.

Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals.

Schacht JP, Anton RF, Randall PK, Li X, Henderson S, Myrick H.

Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. doi: 10.1007/s00213-014-3518-1. Epub 2014 Mar 20.

13.

Neural substrates of resisting craving during cigarette cue exposure.

Brody AL, Mandelkern MA, Olmstead RE, Jou J, Tiongson E, Allen V, Scheibal D, London ED, Monterosso JR, Tiffany ST, Korb A, Gan JJ, Cohen MS.

Biol Psychiatry. 2007 Sep 15;62(6):642-51. Epub 2007 Jan 9.

14.

Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.

Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA.

J Psychopharmacol. 2012 Oct;26(10):1383-90. doi: 10.1177/0269881112449397. Epub 2012 Jun 13.

15.

Severity of nicotine dependence modulates cue-induced brain activity in regions involved in motor preparation and imagery.

Smolka MN, Bühler M, Klein S, Zimmermann U, Mann K, Heinz A, Braus DF.

Psychopharmacology (Berl). 2006 Mar;184(3-4):577-88. Epub 2005 Aug 13.

PMID:
16133128
16.

The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.

Hawk LW Jr, Ashare RL, Lohnes SF, Schlienz NJ, Rhodes JD, Tiffany ST, Gass JC, Cummings KM, Mahoney MC.

Clin Pharmacol Ther. 2012 Feb;91(2):172-80. doi: 10.1038/clpt.2011.317. Epub 2011 Nov 30.

17.
18.

Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial.

Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO.

Nicotine Tob Res. 2011 Oct;13(10):955-64. doi: 10.1093/ntr/ntr103. Epub 2011 Jun 7.

19.

Individual differences in amygdala reactivity following nicotinic receptor stimulation in abstinent smokers.

Sutherland MT, Carroll AJ, Salmeron BJ, Ross TJ, Hong LE, Stein EA.

Neuroimage. 2013 Feb 1;66:585-93. doi: 10.1016/j.neuroimage.2012.10.043. Epub 2012 Oct 27.

20.

Effect of varenicline on aspects of inhibitory control in smokers.

Austin AJ, Duka T, Rusted J, Jackson A.

Psychopharmacology (Berl). 2014 Sep;231(18):3771-85. doi: 10.1007/s00213-014-3512-7. Epub 2014 Mar 21.

PMID:
24652107

Supplemental Content

Support Center